INTRODUCTION
============

Overall survival after breast-conserving surgery (BCS) and adjuvant breast irradiation is equivalent to that after mastectomy for stage I or II breast cancer ([@B1][@B2]). However, the probability of local recurrence is higher in patients treated with BCS compared with those undergoing radical mastectomy ([@B2]). A positive resection margin at the time of BCS is associated with a substantially higher local recurrence rate ([@B3][@B4][@B5]). A positive resection margin is defined by the presence of invasive carcinoma or ductal carcinoma *in situ* (DCIS) at the inked margin of the resected specimen ([@B4][@B6]). In previous studies, several factors such as younger age, larger tumor size, positive lymph nodes, multifocal tumors, lobular histology, and the percentage of *in situ* components were associated with a positive resection margin ([@B7][@B8][@B9][@B10][@B11][@B12]).

Breast magnetic resonance imaging (MRI) has been widely used for the preoperative evaluation of tumor extent in patients with confirmed breast cancer. Previous studies reported that preoperative breast MRI altered the surgical management in approximately 20--30% of patients with breast cancer, leading to a decrease in reoperation rates and an increase in radical mastectomy rates ([@B13][@B14]). The high sensitivity of breast MRI for cancer detection is presumed to improve the selection of patients for BCS and decrease the rates of a positive resection margin at the first BCS attempt ([@B15]). However, there is increasing concern that false-positive findings on preoperative MRI may lead to overtreatment in patients switching from BCS to radical mastectomy, without a clear survival benefit.

Therefore, it is important to determine the preoperative MRI findings and clinicopathological features associated with a positive resection margin during BCS. The purpose of our study was to determine the factors that are associated with a positive resection margin at the time of BCS in patients with breast cancer, with an emphasis on preoperative breast MRI findings.

MATERIALS AND METHODS
=====================

Patients
--------

This retrospective study was approved by our Institution (Gangnam Severance Hospital) Review Board for clinical studies, and the need for obtaining individual consent from the subjects was waived. Between January 2015 and December 2015, we identified 153 consecutive women who had undergone BCS due to breast cancer, invasive cancer, or DCIS, and screened with preoperative MRI. Women receiving chemotherapy prior to surgery (n = 2), those who underwent local excisional biopsy before preoperative MRI (n = 24), and those lacking medical records associated with human epidermal growth factor receptor 2 (*HER2*) status (n = 7) were excluded. Finally, a total of 120 patients who had undergone BCS (mean age, 53.3 years; age range, 27--79 years) were included in our study.

Histopathologic and Immunohistochemical Analysis
------------------------------------------------

Final histopathological results of the surgical specimens were reviewed to determine the tumor size of both the invasive component alone, and the invasive and *in situ* components, the presence or absence of lobular histology, lymphovascular invasion (LVI), and immunohistochemical status. If the final diagnosis was DCIS, the size of the invasive component was recorded as zero. Estrogen receptor (ER) and progesterone receptor (PR) expression was recorded (negative or positive). *HER2*/neu (*HER2*) staging was scored as 0 (negative; no staining), 1+ (negative; faint/barely perceptible incomplete membrane staining), 2+ (equivocal; weak-to-moderate complete membrane staining in \> 10% of the tumor cells or strong complete membrane staining in \< 30% of the tumor cells), or 3+ (positive; strong complete membrane staining in \> 30% of the tumor cells) according to the guidelines of the American Society of Clinical Oncology/College of American Pathologists ([@B16]). Tumors scoring 2+ required further examination using silver-enhanced *in situ* hybridization (SISH) to measure *HER2* amplification. A *HER2*/chromosome 17 ratio greater than 2.2 by SISH indicated *HER2* positive status.

TNM staging was also conducted based on the seventh American Joint Committee on Cancer guidelines ([@B17]). Sentinel node biopsies or axillary nodal dissections were performed, and the N stage was recorded.

Lesion Localization and Evaluation of Resection Margin
------------------------------------------------------

Preoperative tumor localization for nonpalpable lesions was performed by two radiologists (with 5 years and 9 years of experience in breast imaging, respectively) with either mammographically or ultrasound-guided wire placement into the tumor. In cases of non-palpable tumors with microcalcifications, specimen mammography was performed to confirm adequate resection. Intraoperative margin excision and frozen section analysis were performed to evaluate intraoperative margins in all patients. A positive surgical margin was defined as the presence of tumor cells at the inked surface of the resected specimen. The margin was considered negative, in the absence of cancer cells on the inked surface of the resected specimen. We classified the following cases as a positive resection margin: 1) re-excision for positive frozen section analysis during BCS, 2) conversion from attempted BCS to mastectomy, and 3) requirement for further surgical excision.

MR Technique
------------

Breast MRI was performed using a 3T system (Achieva, Philips Medical System, Best, the Netherlands; Discovery MR 750, GE Healthcare, Waukesha, WI, USA) with a dedicated, sensitivity encoding (SENSE), four-channel breast coil. All images were acquired with bilateral axial views in the prone position. The protocol included turbo spin-echo T1- and T2-weighted images and T2-weighted fat suppressed spin-echo series. Dynamic contrast-enhanced MRI was performed with one pre-contrast and five post-contrast dynamic series using a fat-suppressed T1-weighted gradient echo sequence (TR/TE: 4.9/2.4; matrix, 340 x 340; flip angle, 12°; field of view, 34 x 34 cm; slice thickness, 1.5 mm). The acquisition time of each post-contrast series was 74 seconds after a bolus injection of 0.1 mmol gadobutrol (Gadovist, Bayer Healthcare, Berlin, Germany) per kilogram of body weight via an automated injector (Nemoto, Nemoto Kyorindo, Tokyo, Japan), at a rate of 2 mL/s, followed by a 20-mL saline flush. After the examination, subtraction images were obtained by subtracting the unenhanced images from all contrast-enhanced images.

MRI Analysis
------------

Two radiologists (with 5 years and 20 years of experience in breast MRI interpretation, respectively) reviewed the breast MR images in consensus according to the American College of Radiology breast imaging reporting and data system (ACR BIRADS) MRI lexicon ([@B18]). The largest diameters of enhancing lesions were measured in the axial plane of early post-contrast fat-suppressed T1-weighted images and subtraction images. Multifocal cancer was defined as the presence of two or more cancer lesions in the same quadrant, which were separated by normal breast parenchyma. In cases of multifocal lesions, the maximal diameter was not the sum of their diameters, but rather the single largest diameter measured. According to the ACR BIRADS MRI lexicon, enhancing lesions were divided into 2 categories: a mass including foci and non-mass enhancement (NME). We categorized the 120 cases into 2 groups based on the patterns of enhancing lesions on breast MRI. These groups included: 1) mass without NME, 2) NME with or without mass. In patients with a mass, we additionally categorized the shape, margin, and internal enhancement of the mass according to the following criteria: 1) shape (oval, round, or irregular), 2) margin (circumscribed, irregular, or spiculated), and 3) internal enhancement (homogeneous, heterogeneous, rim enhancement, or dark internal septations). In patients with NME, we analyzed the distribution and internal enhancement patterns of the NME according to the following criteria: 1) distribution (focal, linear, segmental, or regional) and 2) internal enhancement patterns (homogeneous, heterogeneous, clumped, or clustered ring). We also assessed breast parenchymal enhancement (BPE) using post-contrast fat-suppressed T1-weighted images and subtraction images. BPE was categorized as minimal, mild, moderate, or marked, and dichotomized into weak (minimal or mild) or strong (moderate or marked) enhancement for statistical analysis.

Statistical Analysis
--------------------

The chi-squared test or Fisher\'s exact test was used to identify the association between each of the preoperative breast MRI findings or clinicopathological factors and the rate of positive resection margins. An independent two-sample *t* test was used for continuous normally distributed variables. Multivariate analysis was performed using logistic regression analysis of statistically significant variables (*p* \< 0.100) via univariate analysis, and the odds ratios (ORs) were estimated. We considered *p* values less than 0.05 as statistically significant. SAS software (version 9.2, SAS Institute Inc., Cary, NC, USA) was used to perform the statistical analyses.

RESULTS
=======

The final histopathological results of the surgical specimens revealed invasive ductal carcinoma in 88 cases, DCIS in 8, invasive cribriform carcinoma in 6, mucinous carcinoma in 5, invasive lobular carcinoma in 3, medullary carcinoma in 3, apocrine carcinoma in 2, microinvasive ductal carcinoma with lobular carcinoma in 1, invasive solid papillary carcinoma in 1, high-grade sarcoma in 1, glycogen-rich clear cell carcinoma in 1, and metaplastic carcinoma in 1 case.

Among the 120 patients, 31 (25.8%) showed a positive resection margin, and 89 (74.2%) had a negative resection margin. Among the 31 cases with a positive resection margin, 17 (54.8%) underwent re-excision for positive frozen section analysis during BCS, 8 (25.8%) received additional local excision, and 6 (19.4%) underwent converted total mastectomy from attempted BCS. The mean tumor size of invasive and *in situ* component was significantly larger in the positive resection margin group compared with the negative resection margin group (2.7 cm vs. 1.8 cm; *p* = 0.015). Age, size of the invasive component of breast cancer, lobular histology, LVI, T stage, N stage, ER, PR, and *HER2* status were not associated with positive resection margins ([Table 1](#T1){ref-type="table"}). The mean tumor size and multifocality of the tumor on MRI were associated with a positive resection margin (*p* = 0.048, *p* = 0.047, respectively). Patterns of enhancing lesions were also significantly associated with a positive resection margin (*p* \< 0.001). Patients with a positive resection margin manifested a higher rate of NME with or without mass on preoperative breast MRI (61.3%) ([Fig. 1](#F1){ref-type="fig"}). However, patients with a negative resection margin had a lower rate of NME with or without mass (14.6%). In cases with NME, the distribution was significantly associated with a positive resection margin (*p* = 0.024). Strong BPE was associated with a positive resection margin (*p* = 0.087) ([Table 2](#T2){ref-type="table"}).

Univariate logistic regression analysis of clinicopathological features revealed that the size of the invasive as well as *in situ* component of the tumor was associated with a positive resection margin (OR = 1.97; *p* = 0.004) ([Table 3](#T3){ref-type="table"}).

[Table 4](#T4){ref-type="table"} summarizes the results of univariate logistic regression analysis of MRI findings. Tumor size, multifocality, and NME with or without mass were associated with positive resection margins (OR = 1.63; *p* = 0.015, OR = 3.42; *p* = 0.035, OR = 9.26; *p* \< 0.001, respectively). In particular, NME with segmental distribution was strongly associated with a positive resection margin (OR = 11.96, *p* = 0.025).

Patterns of enhancing lesions were significantly associated with a positive resection margin. In terms of patterns of enhancing lesions, NME with or without mass was independently predictive of a positive resection margin (OR = 7.00; *p* \< 0.001). Strong BPE was also a weak predictor of positive resection margin (OR = 2.59; *p* = 0.076) ([Table 5](#T5){ref-type="table"}).

DISCUSSION
==========

Currently, BCS is the standard treatment for breast cancer in its early stages. However, a positive resection margin at the time of BCS is associated with a considerably higher risk of local tumor recurrence ([@B3][@B4]). The rate of positive resection margin in our study was 25.8% (31/120) which was within the reported range of 20--70% in the literature ([@B3][@B19]). Larger tumor size, lobular histology, presence of *in situ* components, younger age, multifocal lesions, and LVI are associated with a positive margin ([@B7][@B8][@B9][@B10][@B11][@B12]). Consistent with previous reports, the size of the invasive as well as *in situ* tumor component was associated significantly with a positive resection margin in our study (OR = 1.97; *p* = 0.004). However, younger age and lobular histology (only 4 cases out of 120) were not associated with positive resection margin in our study, probably due to the small number of cases.

The role of preoperative MRI in reducing the rate of positive resection margin in patients with breast cancer treated with BCS is disputed. Turnbull et al. ([@B20]), in a recent randomized controlled trial, reported that addition of preoperative breast MRI was not significantly associated with reduced reoperation rate. Houssami et al. ([@B21]), in a meta-analysis of 9 studies, reported that exposure to preoperative breast MRI increased the overall mastectomy rate (25.5% vs. 18.2%; OR, 1.54 \[*p* \< 0.001\]; adjusted OR, 1.51 \[*p* \< 0.001\]) and failed to reduce the rate of re-excision surgery in patients with initial breast conservation (11.6% vs. 11.4%; OR, 1.02 \[*p* = 0.87\]; adjusted OR, 0.95 \[*p* = 0.71\]). On the other hand, Pengel et al. ([@B22]) reported that preoperative MRI was significantly associated with a lower rate of incomplete excision in patients with invasive ductal carcinoma. Mann et al. ([@B23]) found that preoperative breast MRI reduced the rate of re-excision without increasing the mastectomy rate in patients with invasive lobular carcinoma.

With regard to the MRI features associated with resection margin positivity after BCS, according to Kim et al. ([@B24]), the single NME group showed the highest re-excision rate after BCS (22.2%, *p* = 0.02). Jang et al. ([@B25]) found that a tumor size exceeding 5 cm (OR = 3.81), NME (OR = 2.96), and multifocal lesions (OR = 2.54) on preoperative MRI were positively associated with re-excision. For NME lesions, the segmental distribution pattern predicted re-excision (OR = 10.53) ([@B25]). Similar to a previous study, NME with or without mass was an independent predictor of a positive resection margin compared with mass without NME (OR = 7.00, *p* \< 0.001). Notably, the segmental distribution of NME was strongly associated with a positive resection margin (OR = 11.96, *p* = 0.025). The association between NME and resection margin positivity might be explained by the presence of a DCIS component manifesting as NME. DCIS more commonly presented as NME than mass and many DCIS lesions exhibit segmental or ductal distribution and a clustered ring or clumped internal enhancement ([@B26][@B27][@B28]). Furthermore, many studies have reported that the presence of a DCIS component was significantly associated with a positive resection margin ([@B25][@B29][@B30][@B31][@B32]). Thus, radiologists should be aware that NME on preoperative breast MRI increases the possibility of subsequent positive resection margin status.

In this study, multifocal cancer on MRI was correlated with positive resection margin in univariate analysis, but not in multivariate analysis, which might be explained by the routine use of multiple wire localization for multifocal, nonpalpable lesions in our hospital.

Additionally, a strong BPE was associated with a positive resection margin with borderline significance (OR = 2.59, *p* = 0.76) in our study, similar to a previous study in which strong BPE was a significant independent factor for positive resection margin (OR = 2.39) ([@B33]). BPE varies in degree and distribution in different patients as well as in the same patient over time. Moderate or marked BPE may yield false-positive or false-negative results, and has been associated with abnormal interpretation compared with minimal or mild BPE, especially in the presence of focal, regional, or asymmetric BPE ([@B34][@B35]). Small additional masses or NME around the index cancer may be masked by adjacent enhancing breast tissue leading to a false-negative interpretation ([@B35][@B36]).

There are several limitations to this study. First, because of its retrospective design, patient selection bias might have occurred. We identified 153 consecutive patients with breast cancer who had undergone preoperative MRI and BCS. The patients whose initial surgical plan was switched from BCS to mastectomy due to unfavorable preoperative MRI findings were excluded. Furthermore, 33 (21.6%) of the 153 patients were excluded because they underwent chemotherapy prior to surgery, had a local excisional biopsy, or lacked medical records showing *HER2* status. Second, we did not correlate the MRI findings with the pathologic findings comprehensively. Further studies correlating MRI and pathological findings are needed.

In conclusion, this study found that NME with or without mass detected on preoperative breast MRI was an independent predictive factor for a positive resection margin. More specifically, NME with segmental distribution was strongly correlated with a positive resection margin. In addition, strong BPE was associated with a positive resection margin with borderline significance. Among clinicopathologic factors, the size of the invasive and *in situ* component of the tumor was significantly associated with a positive resection margin. These factors facilitate patient selection and determination of the extent of resection during BCS.

![69-year-old woman with invasive solid papillary carcinoma.\
Preoperative contrast-enhanced T1-weighted subtraction images show segmental clustered ring non-mass enhancement in outer portion of right breast. Patient underwent total mastectomy, which was converted from attempted breast-conserving surgery since positive resection margin was obtained from frozen section analysis. Size of invasive and *in situ* component of tumor was approximately 3.7 cm. Patient tested positive for estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2.](kjr-19-897-g001){#F1}

###### Analysis of Associations between Clinicopathologic Factors and Positive Resection Margin
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                                                       Positive Resection Margin (n = 31)   Negative Resection Margin (n = 89)   *P*
  ---------------------------------------------------- ------------------------------------ ------------------------------------ -------
  Age (years)                                          51.3 ± 10.9                          54.0 ± 11.4                          0.250
  Tumor size (cm) (invasive component)                 1.5 ± 1.2                            1.6 ± 0.8                            0.581
  Tumor size (cm) (invasive and *in situ* component)   2.7 ± 1.8                            1.8 ± 0.8                            0.015
  Histology                                                                                                                      0.274
   Lobular                                             2 (6.5)                              2 (2.3)                              
   Other                                               29 (93.5)                            87 (97.7)                            
  Lymphovascular invasion                                                                                                        0.478
   Present                                             7 (22.6)                             15 (16.9)                            
   Absent                                              24 (77.4)                            74 (83.1)                            
  T stage                                                                                                                        0.289
   Tis                                                 3 (9.7)                              5 (5.6)                              
   T1                                                  20 (64.5)                            58 (65.2)                            
   T2                                                  7 (22.6)                             26 (29.2)                            
   T3                                                  1 (3.2)                              0 (0)                                
  N stage                                                                                                                        0.894
   N0                                                  23 (74.2)                            68 (76.4)                            
   N1                                                  6 (19.4)                             16 (18.0)                            
   N2                                                  2 (6.4)                              4 (4.5)                              
   N3                                                  0 (0)                                1 (1.1)                              
  Estrogen receptor                                                                                                              0.491
   Positive                                            21 (67.7)                            66 (74.2)                            
   Negative                                            10 (32.3)                            23 (25.8)                            
  Progesterone receptor                                                                                                          0.740
   Positive                                            16 (51.6)                            49 (55.1)                            
   Negative                                            15 (48.4)                            40 (44.9)                            
  *HER2*                                                                                                                         0.779
   Positive                                            5 (16.1)                             13 (14.6)                            
   Negative                                            26 (83.9)                            76 (85.4)                            

*HER2* = human epidermal growth factor receptor 2, Tis = carcinoma *in situ*

###### Analysis of Associations between MRI Findings and Positive Resection Margin
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                                          Positive Resection Margin (n = 31)   Negative Resection Margin (n = 89)   *P*
  --------------------------------------- ------------------------------------ ------------------------------------ ----------
  Size on MRI (cm)                        2.7 ± 2.2                            1.9 ± 0.8                            0.048
  Multifocality                                                                                                     0.047
   Yes                                    7 (22.6)                             7 (7.9)                              
   No                                     24 (77.4)                            82 (92.1)                            
  Patterns of enhancing lesions                                                                                     \< 0.001
   Mass without NME                       12 (38.7)                            76 (85.4)                            
   NME with or without mass               19 (61.3)                            13 (14.6)                            
  Mass                                                                                                              
   Shape                                                                                                            0.923
    Oval                                  9 (33.3)                             25 (29.7)                            
    Round                                 5 (18.5)                             15 (17.9)                            
    Irregular                             13 (48.2)                            44 (52.4)                            
   Margin                                                                                                           0.222
    Circumscribed                         10 (37.1)                            18 (21.4)                            
    Irregular                             11 (40.7)                            48 (57.2)                            
    Spiculated                            6 (22.2)                             18 (21.4)                            
   Internal enhancement characteristics                                                                             0.470
    Homogeneous                           4 (14.8)                             9 (10.8)                             
    Heterogeneous                         17 (63.0)                            50 (60.3)                            
    Rim enhancement                       6 (22.2)                             24 (28.9)                            
    Dark internal septations              0 (0)                                0 (0)                                
  NME                                                                                                               
   Distribution                                                                                                     0.024
    Focal                                 4 (21.0)                             9 (69.2)                             
    Linear                                6 (31.6)                             3 (23.1)                             
    Segmental                             8 (42.1)                             1 (7.7)                              
    Regional                              1 (5.3)                              0 (0)                                
   Internal enhancement patterns                                                                                    0.475
    Homogeneous                           1 (5.3)                              0 (0)                                
    Heterogeneous                         4 (21.0)                             6 (46.15)                            
    Clumped                               11 (57.9)                            6 (46.15)                            
    Clustered ring                        3 (15.8)                             1 (7.7)                              
   BPE                                                                                                              0.087
    Weak                                  20 (64.5)                            71 (79.8)                            
    Strong                                11 (35.5)                            18 (20.2)                            

BPE = breast parenchymal enhancement, MRI = magnetic resonance imaging, NME = non-mass enhancement

###### Univariate Logistic Regression Analysis of Clinicopathologic Factors for Predicting Positive Resection Margin
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                                                       OR     95% CI         *P*
  ---------------------------------------------------- ------ -------------- -------
  Age (years)                                          0.98   0.94--1.02     0.249
  Tumor size (cm) (invasive component)                 0.86   0.54--1.35     0.503
  Tumor size (cm) (invasive and *in situ* component)   1.97   1.24--3.11     0.004
  Histology                                                                  
   Lobular                                             3.00   0.40--22.27    0.283
   Other                                               Ref                   
  Lymphovascular invasion                                                    
   Present                                             1.44   0.53--3.94     0.479
   Absent                                              Ref                   
  T stage                                                                    
   Tis                                                 Ref                   
   T1                                                  0.55   0.12--2.49     0.438
   T2                                                  0.45   0.09--2.30     0.334
   T3                                                  4.79   0.04--559.56   0.519
  N stage                                                                    
   N0                                                  Ref                   
   N1                                                  1.15   0.41--3.25     0.795
   N2                                                  1.62   0.29--9.18     0.586
   N3                                                  0.93   0.01--92.69    0.974
  Estrogen receptor                                                          
   Positive                                            0.73   0.30--1.78     0.492
   Negative                                            Ref                   
  Progesterone receptor                                                      
   Positive                                            0.87   0.38--1.98     0.741
   Negative                                            Ref                   
  *HER2*                                                                     
   Positive                                            1.12   0.37--3.46     0.838
   Negative                                            Ref                   

CI = confidence interval, OR = odds ratio, Ref = reference

###### Univariate Logistic Regression Analysis of MRI Findings for Predicting Positive Resection Margin
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                                          OR      95% CI         *P*
  --------------------------------------- ------- -------------- ----------
  Size on MRI (cm)                        1.63    1.10--2.43     0.015
  Multifocality                                                  
   Yes                                    3.42    1.09--10.71    0.035
   No                                     Ref                    
  Patterns of enhancing lesions                                  
   Mass without NME                       Ref                    
   NME with or without mass               9.26    3.65--23.50    \< 0.001
  Mass                                                           
   Shape                                                         
    Oval                                  Ref                    
    Round                                 0.93    0.26--3.29     0.905
    Irregular                             0.82    0.31--2.19     0.693
   Margin                                                        
    Circumscribed                         Ref                    
    Irregular                             0.41    0.15--1.14     0.087
    Spiculated                            0.60    0.18--2.00     0.406
   Internal enhancement characteristics                          
    Homogeneous                           Ref                    
    Heterogeneous                         0.77    0.21--2.81     0.686
    Rim enhancement                       0.56    0.13--2.47     0.446
  NME                                                            
   Distribution                                                  
    Focal                                 Ref                    
    Linear                                3.92    0.65--23.66    0.136
    Segmental                             11.96   1.37--104.62   0.025
    Regional                              6.89    0.06--813.36   0.428
   Internal enhancement patterns                                 
    Homogeneous                           Ref                    
    Heterogeneous                         0.23    0.01--25.38    0.538
    Clumped                               0.58    0.01--60.78    0.818
    Clustered ring                        0.76    0.01--116.21   0.916
   BPE                                                           
    Weak                                  Ref                    
    Strong                                2.17    0.88--5.33     0.091

###### Multivariate Analysis of MRI Findings for Predicting Positive Resection Margin

![](kjr-19-897-i005)

                                  OR     95% CI        *P*
  ------------------------------- ------ ------------- ----------
  Size on MRI (cm)                1.24   0.83--1.84    0.288
  Multifocality                                        
   Yes                            2.04   0.52--7.99    0.308
   No                             Ref                  
  Patterns of enhancing lesions                        
   Mass without NME               Ref                  
   NME with or without mass       7.00   2.38--20.63   \< 0.001
  BPE                                                  
   Weak                           Ref                  
   Strong                         2.59   0.91--7.42    0.076
